Results 71 to 80 of about 5,855,418 (301)

Targeted anti-vascular therapies for ovarian cancer: current evidence [PDF]

, 2013
Ovarian cancer presents at advanced stage in around 75% of women, and despite improvements in treatments such as chemotherapy, the 5-year survival from the disease in women diagnosed between 1996 and 1999 in England and Wales was only 36%.
Mcneish, I., Gore, M., M Hall, Gore, M, C Gourley, Hall, M, Kaye, S, Gourley, C., Ledermann, J, McNeish, I, Jayson, G.; id_orcid, Gourley, C, G Jayson, Jayson, G., Kaye, S., Rustin, G, M Gore, J Ledermann, S Kaye, Perren, T, I McNeish, Hall, M., G Rustin, Rustin, G., Perren, T., T Perren, Jayson, G, Ledermann, J.   +27 more
core   +1 more source

Cancer‐associated mutations in endometriosis reframe a benign disease through molecular oncology

Molecular Oncology, EarlyView.
This review aims to comprehensively analyse cancer‐associated somatic mutations (CAMs) present in endometriotic lesions, emphasizing their biological roles, spatial distribution and implications for translational applications in medicine. By contextualizing a benign state within a genomic framework, this analysis seeks to establish its value as a ...
Clarissa Mujacic, Maria Concetta Vitale, Rita Siino, Emilia Di Giovanni, Carla Ferrante Bannera, Enrico Di Marco, Andrea Gottardo, Tancredi Didier Bazan Russo, Nadia Barraco, Alessandro Perez, Valerio Gristina, Antonio Galvano, Giuseppe Badalamenti, Antonio Russo, Viviana Bazan, Lorena Incorvaia   +15 more
wiley   +1 more source

Anti-müllerian Hormone for the Prediction of Ovarian Response in Progestin-Primed Ovarian Stimulation Protocol for IVF

Frontiers in Endocrinology, 2019
Background: The ability of anti-Müllerian hormone (AMH) to predict ovarian response has been studied extensively in gonadotropin-releasing hormone agonist and antagonist treatments, but no information is available regarding its value in progestin-primed ...
Jialyu Huang, Jiaying Lin, Hongyuan Gao, Yun Wang, Xiuxian Zhu, Xuefeng Lu, Bian Wang, Xinyan Fan, Renfei Cai, Yanping Kuang   +9 more
doaj   +1 more source

Ovarian volume throughout life : a validated normative model [PDF]

, 2013
The measurement of ovarian volume has been shown to be a useful indirect indicator of the ovarian reserve in women of reproductive age, in the diagnosis and management of a number of disorders of puberty and adult reproductive function, and is under ...
Dodwell, Sarah, Wilkinson, A Graham, Sarah K. Dodwell, Andersen, Claus, Wallace, W Hamish B, Claus Y Andersen, Thomas W Kelsey, Richard A Anderson, Wallace, Hamish, Andersen, Claus Y, Wilkinson A. Graham, Dodwell, Sarah K, Wallace W. Hamish B, Andersen Claus Y., A Graham Wilkinson, Kelsey, Thomas W, Kelsey, Tom, Richard A. Anderson, Dodwell Sarah K., Greve, Tine, W. Hamish B Wallace, Thomas W. Kelsey, Claus Y. Andersen, Kelsey Thomas W., Anderson, Richard, Tine Greve, W Hamish B Wallace, Greve Tine, Anderson Richard A., Anderson, Richard A, Sarah K Dodwell, Wilkinson, Graham, A. Graham Wilkinson, Kelsey, Tom; id_orcid   +33 more
core   +1 more source

Prediction of the treatment response in ovarian cancer: a ctDNA approach [PDF]

, 2020
: Ovarian cancer is the eighth most commonly occurring cancer in women. Clinically, the limitation of conventional screening and monitoring approaches inhibits high throughput analysis of the tumor molecular markers toward prediction of treatment ...
Aboulkheyr Es, H, Aboulkheyr Es, H., Totonchi, M, Madjd, Z, Totonchi, M., Sharbatoghli, M, Vafaei, S, Sharbatoghli, M., Mohsen Asadi-Lari, Asadi-Lari, M., Asadi-Lari, M, Mina Sharbatoghli, Zahra Madjd, Mehdi Totonchi, Somayeh Vafaei, Vafaei, S., Hamidreza Aboulkheyr Es, Madjd, Z.   +17 more
core   +1 more source

Castration‐resistant prostate cancer cells are addicted to the high activity of cyclin‐dependent kinase 2

Molecular Oncology, EarlyView.
We show that emergence of castration‐resistant prostate (CRPC) is associated with significant upregulation of cyclins that positively regulate cyclin‐dependent kinase 2 (CDK2) and concomitant downregulation of CDK4 cyclins. This renders CRPC cells dependent on the high activity of CDK2, and CDK2 inhibitors synergistically sensitize CRPC cells to both ...
Joyeeta Chatterjee, Alessia Marin, Shivani Yalala, Harri M. Itkonen   +3 more
wiley   +1 more source

Anti-Mullerian hormone as a predictor of ovarian response to controlled ovarian stimulation

Current Medicine Research and Practice, 2011
Objectives: (i) To establish if anti-Mullerian hormone (AMH) can predict ovarian response better than chronological age and Follicle stimulating hormone (FSH) in IVF/ICSI cycles (ii) To establish cut off levels for AMH that would determine poor response.
R Satwik, A Majumdar, M Kochhar, S Talwar, S Mittal   +4 more
doaj  

Partial FAK suppression promotes tumor growth, an effect reversed by macrophage p110δ PI3K inactivation

Molecular Oncology, EarlyView.
Partial inhibition of focal adhesion kinase (FAK) can paradoxically promote tumor growth, rather than simply producing a weaker antitumor effect than that observed with strong FAK suppression. In breast cancer and melanoma models, targeting p110δ PI3K, particularly in macrophages, counteracted these tumor‐promoting effects, highlighting the importance ...
Lydia Xenou, Niki Tzenaki, Anna Tsapara, Maria Tzardi, Evangelia A. Papakonstanti   +4 more
wiley   +1 more source

Associations between Non-Essential Trace Elements in Women’s Biofluids and IVF Outcomes in Euploid Single-Embryo Transfer Cycles

Journal of Xenobiotics
Previous studies have found inconsistent associations between heavy metals and metalloids (cadmium, lead, mercury, and arsenic), and reproductive outcomes.
Roberto Gonzalez-Martin, Andrea Palomar, Silvia Perez-Deben, Stefania Salsano, Alicia Quiñonero, Laura Caracena, Isabel Rucandio, Rocio Fernandez-Saavedra, Rodolfo Fernandez-Martinez, Estefania Conde-Vilda, Alberto J. Quejido, Juan Giles, Carmen Vidal, Jose Bellver, Francisco Dominguez   +14 more
doaj   +1 more source

Ovarian cancer screening in the general population. [PDF]

, 2007
Despite significant improvements in therapy, ovarian cancer continues to be a leading cause of death amongst women with gynaecological malignancies. Advanced stage at diagnosis is thought to be a major contributor to mortality.
Menon, U., Menon, Usha Dr
core